Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Tick bites are becoming a huge health care issue, as they can cause diseases like Lyme. Due to the recent surge in tick bites throughout the United States, it has become more important to know everything about the situation and the disease.

The Centers for Disease Control and Prevention (CDC) has already issued a warning about a surge in tick bite cases and possible Lyme disease in the Northeastern states, where tick-related emergency room visits have risen. The Midwest is the second most affected region.

Harvard Health states that about 90% of cases have been reported in 14 states: Connecticut, Maine, Virginia, Maryland, Massachusetts, Minnesota, New Jersey, New Hampshire, New York, Pennsylvania, Rhode Island, Vermont, Wisconsin, and West Virginia.

CDC reports ER visits related to tick bites hit their highest levels for spring since 2017. The United States has been fighting with tick-related issues for decades. The nation sees an estimated 476,000 people treated for Lyme disease each year.

Also Read: The Mystery Behind Trump’s Hair-Loss Drug And The Bigger Health Questions It Raises

What Is Lyme Disease?

Lyme disease is caused by a bacterium called Borrelia burgdorferi. This infectious disease is spread by infected ticks. The most common cause of these diseases in humans is bites from blacklegged ticks, though other variants can also be carriers. The Harvard Health says that most patients do not remember being bitten by a tick.

Also Read: Why Thousands Of Black Men In The UK Are Now Being Invited For Prostate Cancer Screening?

Unique Symptoms Of Lyme Disease

Heart Problems

Lyme can impact the cardiac, neurologic, and rheumatologic systems. The CDC says that 1 out of 100 patients has Lyme bacteria in their heart tissues. The condition is also called Lyme carditis.

Brain Fog

Advanced brain imaging shows that Lyme disease brain fog is real. It can lead to various effects, including difficulty focusing, thinking, reading, and absorbing information.

Bell's Palsy

There are 12 essential nerves, also known as the cranial nerves, that originate in the brain and play a crucial role in sensory functions and movements in the different parts of the head, face, neck, and torso. Lyme disease can also affect those nerves, leading to Bell's Palsy.

Eye Problems

Lyme can cause sudden vision loss, damage to the optic nerve, and neurotrophic keratitis. Other symptoms include blurry vision, eye floaters, tearing, and extreme sensitivity to light.

Hearing Problems

The most common Lyme-related hearing issues are tinnitus, vertigo and dizziness, headache, and unilateral sensorineural hearing or hearing loss in one ear.

Arthritis

The disease can cause swollen knees, a low-grade fever, or a limp. It usually starts in the fourth week after being bitten.

Fatigue

This is not just any fatigue, but a weakness that is debilitating. People with a history of Lyme were 8 to 15 times more likely to report severe or moderate fatigue than those who have never had the disease.

President Donald Trump's recent physical examination has been in the news, and now it is about a drug that was omitted in the test, which is making headlines. This very drug is raising questions about the health condition of President Trump, as he has been taking this drug for years. This medication is finasteride, a generic name for Propecia, which is a hair loss drug.

President Trump's recent test report at Walter Reed National Military Medical Center contains a list of drugs that he takes, but in that list, one important name was missing, and that is his hair loss drug, Propecia. According to The Washington Post, when they asked officials if the president still takes that drug, the White House said it was not obligated to reveal the full range of medications the president was taking.

The White House said, “The current report reflects all medications deemed clinically relevant to disclose at this time.” It added, “No additional undisclosed conditions or procedures materially affecting his health status were omitted from this report.”

Though even after the statement of the White House, experts are still questioning his health condition and the hair loss drug. Robert Klitzman, a psychiatrist who leads Columbia University’s master’s program in bioethics, said, “It raises significant questions of what else is possibly not being revealed.”

Steve Joffe, a physician and bioethicist at the University of Pennsylvania Perelman School of Medicine, said to the Post, “There’s a certain level of openness and disclosure that people have a right to expect from someone in whom they place such profound trust.”

President Trump's mysterious drug list, with many omissions, concerns experts as it lacks what matters the most.

Also Read: USDA Flags Suspected New World Screwworm Fly Detection in Texas

Why is Trump's Boasting About Cognitive Test Score Making Experts Question?

President Donald Trump is saying that he has achieved a full score in a very difficult test. He said, “Unlike other US Presidents, none of whom have ever taken an approved, high difficulty, Cognitive Test, I scored a perfect 30 out of 30, considered ‘extreme intelligence.’”

“In fact, this is my fourth such test, all PERFECT or 120 correct answers out of 120 questions asked! Anyone rarely gets a Perfect Score, especially when achieved four times in a row.” He wrote in his post.

He also demanded that the candidates for president and vice president should also go through this kind of test by saying, “In fact, this is my fourth such test, all PERFECT or 120 correct answers out of 120 questions asked! Anyone rarely gets a Perfect Score, especially when achieved four times in a row.”

Also Read: Why Thousands Of Black Men In The UK Are Now Being Invited For Prostate Cancer Screening?

Why Did Experts Question Repeated Testing?

Trump’s claims were immediately questioned by experts like Dr. Jonathan Reiner and Abby Phillip of CNN. They argued that repeated tests may not provide the same value. According to them, as the president had taken the test several times and the questions didn't change that much, it was easy. Other than that, the test is not designed to calculate intellect; it is more of a dementia screening test.

The recent hantavirus outbreak aboard the luxury ship MV Hondius, which drew global attention and raised concerns about the potential for wider spread, has highlighted the need for better therapeutics and vaccines.

The outbreak claimed three lives and infected 13 people. While those affected recovered from the infection, they had contracted the Andes strain, which carries a risk of human-to-human transmission. There is currently no specific antiviral drug or vaccine for the Andes virus.

Now, researchers writing in The Lancet Infectious Diseases have reported early promising results for tocilizumab as a treatment for severe hantavirus pulmonary syndrome (HPS).

The researchers said tocilizumab warrants further evaluation as a treatment for severe hantavirus pulmonary syndrome.

What Did The Study Find?

Also read: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say

The study is based on a case series involving 10 hantavirus patients treated at Hospital Zonal de Bariloche, Argentina, between June 1, 2024, and May 6, 2026.

Tocilizumab is an immunosuppressive medication used to treat severe inflammatory conditions, including severe COVID-19 and autoimmune diseases such as rheumatoid arthritis.

Researchers from San Carlos de Bariloche, Argentina, said that under an ethical framework allowing the emergency use of unproven medications outside clinical trials when no satisfactory alternatives exist, tocilizumab was administered to five eligible patients with laboratory-confirmed severe hantavirus pulmonary syndrome.

Five other patients received standard supportive care without Tocilizumab because they were too sick or the medication was unavailable when treatment was being considered. The case series represents the first descriptive report from a larger ongoing study.

Four of the five patients treated with Tocilizumab survived and were discharged from intensive care, whereas all five patients who did not receive Tocilizumab died shortly after admission to intensive care.

There is currently no approved vaccine or specific antiviral treatment for the Andes strain, underscoring the importance of further research into potential therapies such as tocilizumab.

However, the authors said, "the findings should not be interpreted as evidence for the implementation of routine use of Tocilizumab to treat severe hantavirus pulmonary syndrome, but they do support the need for urgent further research".

What Is Hantavirus?

According to the World Health Organization (WHO), hantaviruses are zoonotic viruses that naturally infect rodents and are occasionally transmitted to humans.

Globally, an estimated 100,000 to 200,000 hantavirus infections occur each year. The majority of cases are reported in Asia, particularly China. Most infections are sporadic or occur in small clusters linked to contact with infected rodents.

In humans, hantavirus infection can cause severe illness and death, although disease severity varies depending on the virus strain and geographical region.

Hantavirus Pulmonary Syndrome

Hantavirus pulmonary syndrome is a severe viral disease caused by the Andes virus, a type of hantavirus endemic in several regions of the Americas, including Argentina and Chile. In recent years, parts of Argentina have seen an increase in hantavirus cases.

The severe respiratory illness can rapidly become fatal. Reported fatality rates range from 20 per cent to 40 per cent, depending on the outbreak setting, quality of medical care, and surveillance capacity.

How Does Hantavirus Spread?

Hantavirus is primarily spread through contact with infected rodents, including exposure to:

• Urine
• Droppings
• Saliva
• Less commonly, scratches or bites from infected rodents